This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

  • identifier


  • Recruitment Status

    Active, not recruiting

  • First Posted

    August 6, 2019

  • Last update posted

    March 26, 2021

Study Description

Brief summary:

CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive or recurrent WHO Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and recurrent Glioblastoma who have failed radiation and chemotherapy, and who are candidates for surgical tumor resection as part of their salvage regimen (planned salvage resection).

  • Condition or Disease:Glioblastoma
  • Intervention/Treatment: Drug: CC-90010
  • Phase: Phase 1/Phase 2

Detailed Description


Study Design

  • Study Type: Interventional
  • Actual Enrollment: 20 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection
  • Actual Study Start Date: January 2020
  • Estimated Primary Completion Date: March 2021
  • Estimated Study Completion Date: August 2021

Arms and interventions

Arm Intervention/treatment
Experimental: Administration of CC-90010
During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
Drug: CC-90010

Outcome Measures

  • Primary Outcome Measures: 1. Intratumoral concentration of CC-90010 in tumor tissue collected intraoperatively [ Time Frame: Up to 4 days following C1D1 ]
    Intratumoral concentration of CC-90010 will be summarized using descriptive statistics
  • 2. Pharmacokinetics - AUC24 [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Area under the plasma concentration time-curve
  • 3. Pharmacokinetics - AUClast [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Area under the plasma concentration time-curve
  • 4. Pharmacokinetics - Cmax [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Maximum observed plasma concentration
  • 5. Pharmacokinetics - Tmax [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Time to maximum plasma concentration
  • 6. Pharmacokinetics - t1/2 [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Terminal half-life
  • 7. Pharmacokinetics - CL/F [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Apparent clearance
  • 8. Pharmacokinetics - V2/F [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Apparent volume of distribution
  • Secondary Outcome Measures: 1. Adverse Events (AEs) [ Time Frame: From enrollment until at least 28 days after completion of study treatment ]
    Number of participants with adverse event

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Men and women ≥ 18 years of age,) with recurrent or progressive WHO Grade II Diffuse
Astrocytoma, Grade III Anaplastic Astrocytoma or recurrent WHO Grade IV Glioblastoma .

2. Subjects must have previously completed standard or a hypofractionated course of
radiation therapy and have been exposed to procarbazine, lomustine and vincristine
(for Grade II Astrocytoma), including those who have progressed on (or not been able
to tolerate due to medical comorbidities or unacceptable toxicity) standard anticancer
therapy, with radiation completed > 12 weeks prior to the first CC-90010 dose (Day 1).

3. Subject must be in first or second recurrence.

4. Subject must have archival tumor tissue suitable for genetic testing and must give
permission to access and test the tissue.

5. Subject is considered an appropriate candidate for surgical resection of the recurrent
tumor tissue (salvage resection).

6. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.

7. Subject must meet laboratory values at screening:

- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L without growth factor support for
7 days (14 days if subject received pegfilgrastim).

- Hemoglobin (Hgb) ≥10 g/dL

- Platelet count (plt) ≥100 x 10^9/L

- Serum potassium concentration within normal range, or correctable with

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x Upper
Limit of Normal (ULN).

- Serum total bilirubin ≤ 1.5 x ULN.

- Serum creatinine ≤ 1.5 x ULN or measured glomerular filtration rate (GFR) ≥ 50
mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr
EDTA or 1 iothalamate, or creatinine clearance of ≥ 50 mL/min using
Cockroft-Gault equation.

- Serum albumin > 3.5 g/dL

- PT (or INR) and APTT ≤ normal range

8. Females and males must agree to contraceptive methods and avoid conceiving throughout
study and up to 46 days (females) and 106 days (males) following last dose of

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject has received anti-cancer therapy (either approved or investigational) within ≤
4 weeks (6 weeks for nitrosoureas) or 5 half-lives, whichever is shorter, prior to
starting CC-90010. If subject received prior immunotherapy (immune checkpoint
inhibitor, vaccine, etc.), a 2 week wash-out is required. For a subject treated with
the Optune-TTF device, a 2 day period without use is required.

2. Toxicities resulting from prior chemotherapy, surgery, or radiotherapy must have
resolved to ≤ NCI CTCAE (version 5.0) Grade 1 prior to starting CC-90010 treatment
(with the exception of Grade 3 alopecia).

3. Subject has undergone major surgery ≤ 4 weeks or minor surgery ≤ 2 weeks prior to
starting CC-90010 or subject who has not recovered from surgery.

4. Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue
or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management, or any
other significant GI disorder that could affect the absorption of CC-90010.

5. Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly
those with a history of and/or risk of perforation and GI tract hemorrhages.

6. Evidence of CNS hemorrhage on baseline MRI or CT scan (except for post-surgical,
asymptomatic Grade 1 hemorrhage that has been stable for at least 4 weeks).

7. Subject who requires increasing doses of corticosteroids to treat symptomatic cerebral
edema within 7 days of study therapy.

8. Known symptomatic acute or chronic pancreatitis.

9. Impaired cardiac function or clinically significant cardiac diseases, including any of
the following:

- LVEF < 45% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO). - Complete left bundle branch or bifascicular block. - Congenital long QT syndrome. - Persistent or clinically meaningful ventricular arrhythmias or atrial fibrillation. - QTcF ≥ 480 msec on Screening ECG (mean of triplicate recordings); a marked baseline prolongation of QT/QTc interval, using Fridericia´s QT correction formula. - History of additional risk factors for Torsade de Pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome. - Use of concomitant medications that prolong the QT/QTc interval. - Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting CC-90010. - Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg). 10. Pregnant or nursing females. 11. Known HIV infection. 12. Known chronic active hepatitis B or C virus (HBV, HCV) infection. 13. Subject with a requirement for ongoing treatment with therapeutic dosing of anticoagulants or for ongoing prophylactic anticoagulation. Low dose low molecular weight heparin for catheter maintenance is allowed. 14. History of concurrent second cancers requiring active, ongoing systemic treatment. 15. Evidence of history of bleeding diathesis. 16. Subject with known prior episodes of non-arteritic anterior ischemic optic neuropathy (NAION) should be excluded from the study. CC-90010 should be used with caution in subjects with retinitis pigmentosa. 17. Subject has any significant medical condition (e.g., active or uncontrolled infection or renal disease), laboratory abnormality, or psychiatric illness that would prevent the subject from participating (or compromise compliance) in the study or would place the subject at unacceptable risk if he/she were to participate in the study. 18. Subject has any condition that confounds the ability to interpret data from the study. 19. Subject with poor bone marrow reserve as assessed by Investigator such as in the following condition: • Requiring regular hematopoietic support (blood or platelet transfusions, erythropoietin, granulocyte colony stimulating factor [GCSF] or other hematopoietic growth factors) 20. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to starting study drug. • Acute symptoms must have resolved and based on investigator assessment in consultation with the medical monitor, there are no sequelae that would place the participant at a higher risk of receiving study treatment. 21. Previous SARS-CoV-2 vaccine within 14 days of starting drug study.

Contacts and Locations



United States, Florida
Mayo Clinic - Jacksonville

United States, Florida
Moffit Cancer Center

United States, Massachusetts
Dana Farber Cancer Institute

Hospital Universitario Fundacion Jimenez Diaz

Hospital Universitario 12 de Octubre

Sponsors and Collaborators



Study Director: Zariana Nikolova, MD, PhD Celgene Corporation

More Information

  • Responsible Party: Celgene
  • Identifier: NCT04047303 History of Changes
  • Other Study ID Numbers: CC-90010-GBM-001, U1111-1235-8082, 2019-000241-12
  • First Posted: August 6, 2019 Key Record Dates
  • Last Update Posted: March 26, 2021
  • Last Verified: March 2021
  • Individual Participant
    Data (IPD) Sharing

  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL:
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: CC-90010
    2nd line or relapsed
    Diffuse Astrocytoma
    Anaplastic Astrocytoma
  • Additional relevant MeSH terms: Astrocytoma Glioblastoma